Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 7:39 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 56 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: GI198745 Clear all

Conditions: Premenstrual Syndrome, PMS, Healthy, Depression
Interventions: Dutasteride, Placebo oral capsule; Drug
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 30 Years to 50 Years · Female only
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2014
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Neoplasms, Prostate
Interventions: dutasteride, placebo, bicalutamide; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years to 90 Years · Male only
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 47
States / cities: Homewood, Alabama • Huntsville, Alabama • Little Rock, Arkansas + 43 more

Conditions: Hypogonadism, Benign Prostatic Hyperplasia
Interventions: Dutasteride, Testosterone gel, Placebo dutasteride; Drug
Lead sponsor: University of Washington; Other
Eligibility: 50 Years and older · Male only
Enrollment: 53 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Neoplasms, Prostate
Interventions: dutasteride; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 50 Years and older · Male only
Enrollment: 2,795 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 73
States / cities: Anchorage, Alaska • Phoenix, Arizona • Little Rock, Arkansas + 68 more

Conditions: Alcohol Use Disorder
Interventions: Dutasteride Capsules, Placebo Capsules; Drug
Lead sponsor: UConn Health; Other
Eligibility: 35 Years to 70 Years
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Farmington, Connecticut

Conditions: Prostatic Hyperplasia
Interventions: dutasteride 0.5mg once daily for 4 years, tamsulosin 0.4mg once daily for 4 years; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 50 Years and older · Male only
Enrollment: 4,844 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 113
States / cities: Birmingham, Alabama • Columbiana, Alabama • Hoover, Alabama + 98 more

Conditions: Prostate Cancer
Interventions: dutasteride, placebo; Drug · Other
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University; Other
Eligibility: 18 Years to 80 Years · Male only
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Prostate Cancer
Interventions: Dutasteride, Placebo; Drug
Lead sponsor: Endeavor Health; Other
Eligibility: 18 Years and older · Male only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 3
States / cities: Chicago, Illinois • Evanston, Illinois

Conditions: Aging
Interventions: Placebo, Testosterone, Anastrazole, Dutasteride; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 50 Years to 80 Years · Male only
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Prostate Cancer
Interventions: Dutasteride, Placebo; Drug · Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 40 Years to 85 Years · Male only
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Prostatic Hyperplasia
Interventions: Treatment sequence A, Treatment sequence B, Treatment sequence C; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Prostate Cancer
Interventions: tamsulosin and/or dutasteride; Drug
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 348 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Cancer, Prostate Neoplasms
Interventions: goserelin with dutasteride, goserelin with bicalutamide and dutasteride, goserelin with bicalutamide and dutasteride and ketoconazole; Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 100 Years · Male only
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2014
U.S. locations: 2
States / cities: Seattle, Washington

Conditions: Alcoholism, Alcohol Abuse, Alcohol Dependence
Interventions: Dutasteride, sugar pill; Drug
Lead sponsor: UConn Health; Other
Eligibility: 18 Years to 70 Years · Male only
Enrollment: 189 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Farmington, Connecticut

Conditions: Prostate Cancer, Castration-resistant, Metastatic
Interventions: testosterone (AndroGel®) with the 5α-reductase inhibitor dutasteride; Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: New York, New York

Conditions: Prostate Cancer
Interventions: PCUR-101, Dutasteride 0.5 mg, Abiraterone and Prednisone; Drug
Lead sponsor: Pellficure Pharmaceuticals, Inc; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 2
States / cities: Ann Arbor, Michigan • Omaha, Nebraska

Conditions: Prostate Cancer
Interventions: Ketoconazole, Hydrocortisone and Dutasteride; Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2012
U.S. locations: 6
States / cities: Baltimore, Maryland • Boston, Massachusetts • Portland, Oregon + 1 more

Conditions: Obesity, Insulin Resistance
Interventions: Anastrazole, Testosterone, Dutasteride, GnRH antagonist; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 24 Years to 51 Years · Male only
Enrollment: 57 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2009
U.S. locations: 2
States / cities: San Diego, California

Conditions: Prostatic Hyperplasia
Interventions: dutasteride; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 20 Years to 45 Years · Male only
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Benign Prostatic Hyperplasia (BPH)
Interventions: Tolterodine ER 4mg, Placebo, Pre-randomization Dutasteride; Drug
Lead sponsor: Siami, Paul F., M.D.; Other
Eligibility: 50 Years and older · Male only
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Newburgh, Indiana

Conditions: Kennedy's Disease, Spinal and Bulbar Muscular Atrophy
Interventions: Dutasteride, Placebo; Drug
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: 18 Years and older · Male only
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Prostatic Hyperplasia
Interventions: Dutasteride; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 50 Years and older · Male only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 11
States / cities: Long Beach, California • New Britain, Connecticut • Trumbull, Connecticut + 8 more

Conditions: Gonadotropin Deficiency
Interventions: Testosterone 1% Gel, Acyline, Dutasteride, Ketoconazole, HCG, placebo dutasteride, placebo ketoconazole; Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 55 Years · Male only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Prostate Cancer
Interventions: Enzalutamide and Dutasteride or finasteride; Drug
Lead sponsor: University of Rochester; Other
Eligibility: 65 Years to 99 Years
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2023
U.S. locations: 2
States / cities: Rochester, New York • Milwaukee, Wisconsin

Search by objective public record fields.

Dutasteride to Treat Women With Menstrually Related Mood Disorders

Prostate Cancer Study In Men Who Have Failed First-Line Androgen Deprivation Therapy

TRADE-Testosterone Replacement and Dutasteride Effectiveness

ARI103094-Follow-Up Study for REDUCE Study Subjects

Dutasteride Treatment for Reducing Heavy Drinking in AUD: Predictors of Efficacy

Benign Prostatic Hyperplasia Trial With Dutasteride And Tamsulosin Combination Treatment

Dutasteride Followed By Ultrasound-Guided Biopsy in Finding Prostate Cancer

Effect of Dutasteride on Androgen-Response Gene Expression in Patients With Advanced Prostate Cancer

Testosterone-Driven Growth-Hormone (GH) Secretion in Aging Men

Role of Dutasteride in Patients Undergoing 3D Mapping Biopsy in Early Stage Prostate Cancer

Comparative Bioavailability of Two Fixed Dose Combination (FDC) Formulations of Dutasteride and Tamsulosin Hydrochloride Relative to Co-administration of Dutasteride With Tamsulosin Hydrochloride in Healthy Male Subjects Under Fed and Fasted States

Study of Tamsulosin and/or Dutasteride to Relieve Urinary Symptoms After Brachytherapy for Localized Prostate Cancer

Maximal Suppression of the Androgen Axis in Clinically Localized Prostate Cancer

Dutasteride Treatment for the Reduction of Heavy Drinking in Men

Exogenous Testosterone Plus Dutasteride for the Treatment of Castrate Metastatic Prostate Cancer

Study of PCUR-101 in Combination With ADT in Patients With mCRPC

Ketoconazole, Hydrocortisone and Dutasteride in Asymptomatic Hormone Refractory Prostate Cancer

Metabolic Effects of Steroids in Obese Men

Study to Compare the Bioavailability of Dutasteride Novel Formulation Form to the Soft Gel Capsule Form in Healthy Male Subjects

Dutasteride With Tolterodine ER or Placebo to Treat Lower Urinary Tract Symptoms (LUTS)

Dutasteride to Treat Spinal and Bulbar Muscular Atrophy (SBMA)

Effect Of Dutasteride On Intraprostatic Dihydrotestosterone (DHT) Levels

ITT-5 Mechanisms of Spermatogenesis in Man

Enzalutamide & Dutasteride/Finasteride as 1st Line Treatment for Patients =/> 65 Years Old With Prostate Cancer.